Promontory Therapeutics Inc.

Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting

by

NEW YORK, June 2, 2023 /PRNewswire/ — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, announces preliminary data from a Phase 2 clinical trial of the company’s lead therapeutic candidate, PT-112, in patients with recurrent thymic epithelial tumors (TETs), specifically thymoma and thymic carcinoma. The trial is being conducted under … Read more

Promontory Therapeutics to Participate in Business Development Strategies Panel at the Sachs 9th Annual Immuno-Oncology Innovation Forum

by

The company will also present an update on its corporate and clinical progress at the event NEW YORK, May 31, 2023 /PRNewswire/ — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will participate in a panel discussion on maximizing value in a capital efficient manner at the Sachs 9th … Read more